Evaluation of biological pathways involved in chemotherapy response in breast cancer by Tordai, Attila et al.
Open Access
Available online http://breast-cancer-research.com/content/10/2/R37
Page 1 of 9
(page number not for citation purposes)
Vol 10 No 2 Research article
Evaluation of biological pathways involved in chemotherapy 
response in breast cancer
Attila Tordai1,2, Jing Wang3, Fabrice Andre4, Cornelia Liedtke1, Kai Yan3, Christos Sotiriou5, 
Gabriel N Hortobagyi1, W Fraser Symmans and Lajos Pusztai1
1Department of Breast Medical Oncology, The University of Texas M. D. Anderson Cancer Center, PO Box 301439, Houston, TX 77230-1439, USA
2Department of Molecular Diagnostics, National Medical Center, Szabolcs utca 33-35, 1135 Budapest, Hungary
3Department of Bioinformatics and Computation Biology, The University of Texas M. D. Anderson Cancer Center, PO Box 301439, Houston, TX 
77230-1439, USA
4Unit UPRES03535, Institut Gustave Roussy, 39 Rue Camille Desmoulins, 94805 Villejuif, France
5Jules Bordet Institut, 121 Boulevard de Waterloolaan, Brussels 1000, Belgium
Corresponding author: Lajos Pusztai, lpusztai@mdanderson.org
Received: 19 Dec 2007 Revisions requested: 7 Feb 2008 Revisions received: 2 Apr 2008 Accepted: 29 Apr 2008 Published: 29 Apr 2008
Breast Cancer Research 2008, 10:R37 (doi:10.1186/bcr2088)
This article is online at: http://breast-cancer-research.com/content/10/2/R37
© 2008 Tordai et al.; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction Our goal was to examine the association between
biological pathways and response to chemotherapy in estrogen
receptor-positive (ER+) and ER-negative (ER-) breast tumors
separately.
Methods Gene set enrichment analysis including 852
predefined gene sets was applied to gene expression data from
51 ER- and 82 ER+ breast tumors that were all treated with a
preoperative paclitaxel, 5-fluoruracil, doxorubicin, and
cyclophosphamide chemotherapy.
Results Twenty-seven (53%) ER- and 7 (9%) ER+ patients had
pathologic complete response (pCR) to therapy. Among the ER-
tumors, a proliferation gene signature (false discovery rate
[FDR] q = 0.1), the genomic grade index (FDR q = 0.044), and
the E2F3 pathway signature (FDR q = 0.22, P = 0.07) were
enriched in the pCR group. Among the ER+  tumors, the
proliferation signature (FDR q = 0.001) and the genomic grade
index (FDR q = 0.015) were also significantly enriched in cases
with pCR. Ki67 expression, as single gene marker of
proliferation, did not provide the same information as the entire
proliferation signature. An ER-associated gene set (FDR q =
0.03) and a mutant p53 gene signature (FDR q = 0.0019) were
enriched in ER+ tumors with residual cancer.
Conclusion Proliferation- and genomic grade-related gene
signatures are associated with chemotherapy sensitivity in both
ER- and ER+ breast tumors. Genes involved in the E2F3 pathway
are associated with chemotherapy sensitivity among ER- tumors.
The mutant p53 signature and expression of ER-related genes
were associated with lower sensitivity to chemotherapy in ER+
breast tumors only.
Introduction
Drug resistance is caused by multiple mechanisms that oper-
ate simultaneously in tumors. A large number of biological
functions, including transmembrane trafficking, DNA repair,
stress response, proliferation, and apoptosis, may affect the
sensitivity of a cell to chemotherapy. Other, yet-to-be-identified
mechanisms may also play a role. Preoperative chemotherapy
provides an attractive clinical setting to study mechanisms of
drug resistance in patients.
Chemotherapy before surgery is used in the treatment of
newly diagnosed, stage II-III breast tumors because it fre-
quently reduces tumor size and improves surgical outcome
[1]. Among patients who receive preoperative chemotherapy,
up to 25% to 30% (depending on the type of treatment) expe-
rience complete eradication of the invasive cancer in the
breast and regional lymph nodes after completion of 3 to 6
months of chemotherapy [2]. This favorable response is called
pathologic complete response (pCR) and it indicates an
extremely chemotherapy-sensitive tumor and also heralds
excellent long-term cancer-free survival [3]. We previously
BUM = beta-uniform mixture; ER = estrogen receptor; FDR = false discovery rate; GGI = genomic grade index; GSEA = gene set enrichment analysis; 
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conducted a pharmacogenomic study that included 133
patients with newly diagnosed breast cancer who received
preoperative chemotherapy with paclitaxel followed by 5-fluor-
ouracil, doxorubicin, and cyclophosphamide. All patients
underwent a one-time, pretreatment, fine-needle biopsy of the
cancer for gene expression analysis. The goal of the study was
to discover gene-expression-based predictors of pCR. Our
previous analysis focused on discovering the best possible
multigene predictor without considering the function of any of
the genes [4]. The goal of the present analysis is to examine
an association between known biological pathways and
response to chemotherapy.
Lists of genes (that is, gene sets) that represent various bio-
logical pathways were assembled from the literature. We used
gene set enrichment analysis (GSEA) to examine the correla-
tion between these a priori-defined gene sets and chemother-
apy response [5]. Clinical experience as well as molecular
analysis of breast tumors indicate that estrogen receptor-pos-
itive (ER+) and ER-negative (ER-) tumors are two different
types of neoplastic disease of the breast [6,7]. It is plausible
that different molecular mechanisms may determine response
or resistance to chemotherapy in these two types of breast
tumor. Therefore, we performed our analysis separately for
ER+ and ER- tumors.
Materials and methods
Patients
This study included 51 ER- and 82 ER+ tumors from patients
with newly diagnosed stage I-III breast cancer. Each patient
had a fine-needle aspiration of the cancer before starting
chemotherapy. These needle aspiration samples contain
approximately 80% neoplastic cells and few or no stromal
cells or normal breast epithelium [8]. All patients were treated
with 6 months of preoperative chemotherapy with paclitaxel
followed by 5-fluorouracil, doxorubicin, and cyclophospha-
mide. Patients underwent surgery after completion of chemo-
therapy, and the resection specimens were examined by a
pathologist to measure residual cancer. For the purpose of our
analysis, tumor response was dichotomized as pCR, defined
as no residual invasive cancer in the breast and lymph nodes,
or as residual disease (RD), which included patients with any
degree of invasive cancer that survived preoperative chemo-
therapy. The reason for this dichotomization was that pCR is a
strong surrogate for long-term cancer-free survival and there-
fore a marker of long-term benefit from therapy [2,3]. It remains
unknown to what extent patients who achieve less than pCR
benefit from chemotherapy in terms of improved survival. This
categorization of pathologic response allowed us to compare
biological pathways between tumors with extreme chemother-
apy sensitivity (pCR) and the rest (RD). There were not
enough cases with tumor progression during treatment in our
study to form a third group including extreme chemotherapy-
resistant tumors.
ER status was determined from routine pathological assess-
ment by immunohistochemistry. Following standard clinical
practice, the cutoff for ER positivity was greater than or equal
to 10% positive tumor cells. This study was approved by the
institutional review boards of the M. D. Anderson Cancer
Center (Houston, TX, USA), and all patients signed an
informed consent form for voluntary participation. Clinical
characteristics of the patients are presented in Table 1.
Gene expression analysis
Gene expression profiling was performed by using Affymetrix
U133A Gene Chips (Affymetrix, Santa Clara, CA, USA) follow-
ing standard operating procedures as described previously
[4]. We normalized the gene expression data using dChip
V1.3 software [9] to a single reference array. The normalized
gene expression values were transformed to a log10 scale for
further analysis. The complete microarray data are available at
the M. D. Anderson Cancer Center bioinformatics website
[10]. To identify differentially expressed genes between cases
with pCR and RD, we performed the unequal variance t test
on each probe set. Because of the multiple comparisons,
many low P values are expected by chance alone. Under the
null hypothesis that no genes provide useful information, the
distribution of P values should be uniform. If, on the other
hand, some genes do provide useful information about pre-
dicting response, we would expect an overabundance of small
P values (above what chance might produce). We can capture
this situation by modeling the distribution of the P values as a
beta-uniform mixture (BUM). This analysis was used to esti-
mate false discovery rates (FDRs) that accompany particular P
values derived from the t test [11]. All analysis was performed
using the R package (version 2.3.1).
Gene set enrichment analysis
GSEA was applied to assess the association between pCR,
RD, and 852 distinct a priori-defined gene sets. The goal of
the GSEA is to determine whether members of a particular
gene set (that is, a list of 15 to 500 probe sets that correspond
to genes that define a biological pathway) tend to occur
toward the top or the bottom of a rank-ordered gene list includ-
ing all gene expression measurements [5]. We ranked all
probe sets based on their correlation with pCR. Three groups
of gene sets were tested: The first included 319 distinct gene
sets corresponding to probes associated with 295 different
cryptogenic bands on 24 chromosomes, and the second
included 522 different gene sets corresponding to genes
involved in various metabolic and signaling pathways. A
detailed description of these gene sets and how they were
assembled was presented by Subramanian and colleagues
[5]. The third group contained 11 gene sets of various onco-
genic or drug-resistance-related pathways. These included 5
distinct oncogenic pathways that were defined as genes over-
expressed in normal human mammary epithelial cells trans-
fected with Myc, Ras, E2F3, β-catenin, and Src oncogenes,
respectively, and were described by Bild and colleagues [12].Available online http://breast-cancer-research.com/content/10/2/R37
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We also included a mutated p53-associated gene set that
was defined as genes overexpressed in p53 mutant compared
to p53 normal breast cancers [13]. It has been suggested that
this gene expression signature can distinguish tumors with
wild-type and mutant p53 and it may outperform direct p53
gene sequencing as a predictor of prognosis and therapeutic
response. We also assessed one ER-associated gene set that
contained genes that were most highly coexpressed with the
ER gene in human breast cancer microarray data developed
by Symmans and colleagues [14]. This gene set did not
include the ER gene itself. We also examined the genomic
grade index (GGI) that represents genes that are differentially
expressed between low-grade and high-grade human breast
tumors and that were identified by Sotiriou and colleagues
[15]. One prognostic signature that was derived by comparing
gene expression profiles of tumors that recurred with those
that did not was also tested. This prognostic signature was
first reported by Wang and colleagues [16]. A proliferation sig-
nature set reported by Whitfield and colleagues [17] that
includes genes involved in cell proliferation was also exam-
ined. Finally, we also assessed an ATP-binding cassette trans-
porter (ABC) gene set that included genes involved in drug
transport and was previously shown by Szakacs and col-
leagues [18] to predict chemotherapy response in cell lines.
Gene annotations were based on UniGene Build 185, which
was used to match the genes in each of the above publica-
tions to probe sets on Affymetrix U133A Gene Chips. The
gene sets are listed in Table 2, and a complete list of all probe
sets that comprise each of the 852 sets is provided in Supple-
mentary Table 1.
Gene set enrichment score was calculated as reported previ-
ously [5]. This score is a measure of the degree to which a
gene set is over-represented at the extremes of the entire
ranked gene list. Significance was assessed by permuting
class labels (that is, response category) and calculating
enrichment scores for the permuted data sets that yielded a
Table 1
Patient characteristics





T0 0 1 (1%)
T1 8 (16%) 4 (5%)
T2 24 (47%) 46 (56%)
T3/4 19 (37%) 31 (38%)
Histological grade
Grade 1 0 2 (2%)
Grade 2 6 (12%) 45 (55%)
Grade 3 43 (84%) 31 (38%)
Unknown 2 (4%) 4 (5%)
Lymph node status
Positive 38 (75%) 55 (67%)
Negative 13 (25%) 27 (33%)
HER2 overexpressed or amplified
Yes 18 (35%) 15 (18%)
No 32 (63%) 67 (82%)
Unknown 1 (2%) 0
Pathologic complete response
Yes 27 (53%) 7 (9%)
No 24 (47%) 75 (91%)
ER, estrogen receptor.Breast Cancer Research    Vol 10 No 2    Tordai et al.
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null distribution. Nominal P value for a score was derived from
comparison with this null distribution. To adjust for multiple
hypothesis testing, the FDR q value was calculated for each
gene set. The q value could be considered as an FDR-
adjusted P value. However, unlike P values, which express the
probability of a false-positive result for a single test, the q value
gives an estimate of the proportion of false positives for a set
of results [19]. Gene sets with an FDR q value of less than or
equal to 0.25 were considered to be of interest, which indi-
cates that the result is likely to be valid three out of four times
and represents a previously proposed cutoff in the literature
[5]. GSEA was performed using the R package of GSEA (ver-
sion 1.0) provided by the Broad Institute of the Massachusetts
Institute of Technology (Cambridge, MA, USA).
Results
Differentially expressed genes
Twenty-seven out of 51 patients (53%) had pCR among the
ER- tumors, and 7 out of 82 (9%) among the ER+ tumors. The
much lower response rate in ER+ tumors is consistent with
previous reports in the clinical literature [1-4]. First, we exam-
ined whether we could identify differentially expressed genes
between cases with pCR and RD by means of the unequal var-
iance t test. We performed this analysis separately for ER- and
ER+ tumors. Figure 1 shows results of the BUM analysis of the
P values from the t test. In ER- tumors, the FDR associated
with the lowest P  value (P  ≤ 0.00087) was 40%. In ER+
tumors, the FDR was close to 100% for all observed P values.
The scarcity of low P values in the ER+ group is due to the
unbalanced sample size (that is, few informative cases, 7 pCR
only) and suggests an underpowered analysis that violates t
test assumptions.
These observations indicate that, in these two data sets, the t
test cannot reliably identify differentially expressed genes.
However, these results do not necessarily indicate that there
are no real transcriptional differences between cases with
pCR compared with RD when ER+ and ER- tumors are ana-
lyzed separately. It is possible that no individual gene meets
the threshold for statistical significance after correcting for
multiple hypothesis testing because the transcriptional differ-
ences are modest relative to the technical noise and biological
variability that are present in the data. Analysis at the single
gene level may also miss small but coordinated expression dif-
ferences in a larger number of genes that could belong to
important biological pathways. In some situations, small coor-
dinated change in the expression of many genes that belong
to a particular metabolic pathway can have robust functional
consequences [20]. Such subtle gene expression differences
would not be identified easily by pairwise comparisons using
t-statistics. Different analytical tools, including GSEA, were
developed to test for potentially relevant but small-scale tran-
scriptional differences in predefined sets of genes.
Gene set enrichment analysis to identify pathways 
associated with complete response to preoperative 
chemotherapy
We applied GSEA to the 51 ER- tumors. Only 3 gene sets out
of the 853 were enriched with an FDR q value of less than or
equal to 0.25. These gene sets included (a) the proliferation
set (FDR q = 0.1, P = 0.05) (Figure 2a and Supplementary
Table 2
Gene sets used in this analysis
Functional pathway Number of probe sets (corresponding number of known genes) Reference
Cytogenetic sets, n = 319 sets 15–500 (variable) Subramanian, et al. [5]
Functional sets, n = 522 sets 15–500 (variable) Subramanian, et al. [5]






Genomic grade index, 1 set 242 (183) Sotiriou, et al. [15]
76-gene prognostic signature, 1 set 76 (76) Wang, et al. [16]
Proliferation signature, 1 set 74 (44) Whitfield, et al. [17]
ABC transporter gene set, 1 set 61 (47) Szakacs, et al. [18]
Mutant p53 signature, 1 set 25 (21) Miller, et al. [13]
Estrogen receptor-associated gene set, 1 set 200 (187) Symmans, et al. [14]Available online http://breast-cancer-research.com/content/10/2/R37
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Figure 1a), (b) the GGI set (FDR q = 0.04, P = 0.08) (Figure
2b and Supplementary Figure 1b), and (c) the E2F3 pathway
gene set (FDR q = 0.2, P = 0.07) (Figure 2c and Supplemen-
tary Figure 1c). All of these were enriched in the group with
pCR, whereas no gene set was enriched in the group with
residual cancer.
Figure 1
Distribution of P values computed from the unequal variance t test in patients with estrogen receptor (ER)-negative and ER-positive tumors Distribution of P values computed from the unequal variance t test in patients with estrogen receptor (ER)-negative and ER-positive tumors. (a) 
Gene expressions were compared between ER-negative tumors that had pathologic complete response and those that had a lesser response to 
preoperative chemotherapy. The resulting P values for all comparisons were modeled as beta-uniform mixture. The straight line indicates the contri-
bution of the uniform component, and the curved line is the fitted beta-distribution from the observed values. Deviation above the straight line indi-
cates P values that may represent true discovery. (b) Distribution of P values in patients with ER-positive tumors.
Figure 2
Gene set enrichment results for estrogen receptor-negative breast tumors Gene set enrichment results for estrogen receptor-negative breast tumors. Running enrichment scores (RESs) and the location of each probe set 
within the complete rank-ordered gene list for each gene set. The dotted line on the left indicates the position of the maximum RES, and the dotted 
line on the right indicates the zero position of the ranking metric score. (a) Proliferation set (probe set n = 74). (b) Genomic grade index (probe set 
n = 242). (c) E2F3 pathway (probe set n = 173). Heat maps corresponding to these plots are provided in Supplementary Figure 1. pCR, pathologic 
complete response; RD, residual disease.Breast Cancer Research    Vol 10 No 2    Tordai et al.
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We performed the same analysis on the 82 ER+ cases. Two
gene sets were enriched in the group with pCR: the prolifera-
tion set (FDR q = 0.001, P = 0.002) (Figure 3a and Supple-
mentary Figure 2a) and the GGI set (FDR q = 0.015, P = 0.01)
(Figure 3b and Supplementary Figure 2b). In the group with
residual cancer, two other gene sets showed enrichment: the
ER-associated gene list (FDR q = 0.03, P = 0.04) (Figure 3c
and Supplementary Figure 2c) and the mutant p53 gene sig-
nature (FDR q = 0.0019, P = 0.07) (Figure 3d and Supple-
mentary Figure 2d). The complete list of probes and genes
included in the five enriched gene sets is presented in Supple-
mentary Table 2.
These results indicate that higher expression of proliferation-
related genes characterized tumors with pCR among both ER-
and ER+ tumors. There are several single gene markers of pro-
liferative activity; the one that is used most commonly in the
clinic is Ki67 (which was also included in the proliferation gene
set). We therefore examined whether measuring Ki67 (MIK67)
mRNA expression alone is sufficient to separate cases with
pCR from those with RD after chemotherapy. Ki67 expression
is measured by two distinct Affymetrix probe sets:
'212021_s_at' and '212023_s_at'. In ER- tumors, neither of
these probe sets was significantly differentially expressed
according to pathologic response to chemotherapy (unequal
variance  t  test,  P  = 0.97 and 0.92, respectively). In ER+
Figure 3
Gene set enrichment results for estrogen receptor (ER)-positive breast tumors Gene set enrichment results for estrogen receptor (ER)-positive breast tumors. Results are presented as in Figure 2. (a) Proliferation set. (b) 
Genomic grade index. (c) ER-associated genes (probe set n = 201). (d) Mutant p53 gene signature (probe set n = 25). Heat maps corresponding 
to these plots are provided in Supplementary Figure 2. pCR, pathologic complete response; RD, residual disease.Available online http://breast-cancer-research.com/content/10/2/R37
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tumors, one of the two probe sets ('212023_s_at') showed
borderline significant overexpression in the pCR group (P =
0.06).
Also, since the ER-associated gene set was enriched in ER+
breast tumors with RD after chemotherapy, we examined
whether quantitative assessment of the ER (ESR1) mRNA
alone could provide the same information [21]. There was no
statistically significant difference in ER mRNA expression lev-
els (probe set '205225_at') between cases with complete
response and those with residual cancer after chemotherapy
(unequal variance t test, P = 0.09) among the ER+ tumors.
Discussion
In the present study, we examined whether we could find indi-
vidual genes or gene sets that are significantly associated with
extreme chemotherapy sensitivity in ER+  and ER-  breast
tumors, respectively. These two major types of breast tumor
differ in the expression of thousands of genes [6,7,22]. They
also have substantially different sensitivity to cytotoxic treat-
ment; ER+ tumors are generally less sensitive to chemotherapy
than ER- tumors [2]. Therefore, when these tumors are ana-
lyzed together, sensitivity markers tend to identify ER- tumors
and are often dominated by genes that reflect the ER status of
the tumor [4]. To identify markers of response that are inde-
pendent of ER status, we analyzed these two groups of breast
tumors separately. To our surprise, the commonly used
approach which performs genewise comparison between
responders and nonresponders failed to identify any genes
that could be declared differentially expressed with statistical
confidence. The estimated FDR was greater than 40% among
the top differentially expressed genes in ER- tumors and the
FDR was even higher among ER+ tumors. These findings are
in contrast with the results that can be obtained when the
entire patient cohort is analyzed together. When we searched
for differentially expressed genes including both ER- and ER+
cases, we could identify over 400 genes with an FDR of less
than or equal to 1% [4].
We next examined whether coordinated but relatively small-
scale differences in the expression of sets of genes that
belong to functional pathways are associated with response.
Such small-scale differences at the individual gene level may
not be readily identified by t-statistics but GSEA may be able
to detect these. Two gene sets emerged as strongly enriched
in tumors with pCR to chemotherapy in both ER+ and ER-
tumors. These included 44 genes (corresponding to 74 probe
sets) involved in cell proliferation and 183 genes (correspond-
ing to 242 probe sets) that distinguish histologically high-
grade tumors from low-grade tumors. These observations are
consistent with the literature that suggests that highly prolifer-
ative tumors are more sensitive to cytotoxic treatment in gen-
eral [23]. However, there is no consensus on how to best
measure proliferative activity [24]. To underscore the power of
gene set analysis, we noted that the proliferation signature as
a whole was significantly over-represented in highly chemo-
therapy-sensitive tumors. However, a commonly used prolifer-
ation marker, Ki67, which was included in the signature,
showed no significant overexpression when tested alone. It is
also well documented in the clinical literature that high histo-
logical grade is associated with better response to preopera-
tive chemotherapy [25]. It was reassuring to observe that the
same association holds up for the GGI too.
We also made three novel observations. Our results indicate
that the expression of genes involved in the E2F3 pathway may
be associated with a high degree of chemotherapy sensitivity
in ER- tumors. Given that the E2F3 family of transcription fac-
tors plays a critical role in regulating cell cycle progression,
this association is not surprising [26]. Nevertheless, no previ-
ous reports linked E2F3 activity to chemotherapy response. It
is also intriguing that no association between E2F3 pathway
and pCR was seen in ER+ tumors. We also observed higher
expression of mutant p53-associated genes in relatively
chemotherapy-resistant ER+ breast tumors. A similar associa-
tion was not seen among ER- tumors, which suggests that p53
dysregulation may have different consequences on chemo-
therapy sensitivity depending on the hormone receptor status
of the tumor. This may partly explain the conflicting results
about the role of p53 mutation in chemotherapy response in
the literature. Some studies suggested that functional p53
defects predict for increased sensitivity to anthracycline chem-
otherapy [27]. Others reported that p53 mutations are associ-
ated with resistance to anthracyclines [28,29]. It has also been
shown that breast cancer cell lines exhibit different transcrip-
tional response to chemotherapy in vitro depending on their
hormone receptor status and molecular class. For example,
the expression of p21, a p53-regulated protein, was highly
induced in ER+ cells but only weakly induced in ER- breast can-
cer cell lines in response to anthracycline exposure [30]. This
suggests that p53-mediated apoptosis may be more important
in ER+ (luminal) than in ER- (basal-like) cells. Future biomarker
studies will need to consider the possibility that the predictive
value of a biomarker may depend on the molecular subtype of
the tumor [31].
We also observed that those ER+ tumors that had low expres-
sion of ER-associated genes were more sensitive to chemo-
therapy. This was independent of the actual level of ER
expression and indicates that some ER+ breast tumors do not
posses the full transcriptional signature of ER activity. These
tumors showed increased chemotherapy sensitivity.
Our study has limitations. All patients received combination
chemotherapy that represents the current standard of care for
this patient population. This makes our observations more rel-
evant for clinical practice but at the same time limits our ability
to decipher drug-specific response pathways. This could have
biased our results toward detecting 'generic' drug sensitivity
pathways such as proliferation. The gene sets that we testedBreast Cancer Research    Vol 10 No 2    Tordai et al.
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were assembled from the published literature and often con-
tain overlapping genes represented in multiple gene sets. Our
current knowledge of biology is incomplete and does not allow
the precise definition of all the genes that contribute to a given
biological process or represent a unique molecular pathway.
This may explain why the majority of the 852 gene sets that we
examined, including numerous apoptosis and signaling path-
ways, did not show enrichment by chemotherapy response. It
is also important to consider that GSEA is a method to dem-
onstrate that the expression of a given gene set is over-repre-
sented in the top or bottom of particular gene lists ranked by
correlation with clinical outcome. However, this method can-
not be used to predict response in a new case. How to trans-
late GSEA results into a prospective single-sample response
predictor remains an unsolved bioinformatics challenge.
Conclusion
We found that it is difficult to identify individual genes associ-
ated with chemotherapy response with statistical confidence
when ER- and ER+ breast tumors are analyzed separately. In
contrast, GSEA revealed several biological pathways that
were associated with response. These included proliferation-
related genes and the GGI that were enriched in tumors with
high sensitivity to chemotherapy regardless of ER status.
Genes included in the E2F3 pathway were also enriched in
ER- and highly chemotherapy-sensitive tumors. On the other
hand, a mutant p53 gene expression signature and a set of
highly ER-associated genes were enriched in ER+ and chem-
otherapy-resistant tumors. These results suggest that prolifer-
ative activity confers increased sensitivity to chemotherapy in
breast cancer in general, whereas other biological pathways
such as p53 mutation and E2F3 activation may be more selec-
tive and influence chemotherapy sensitivity only in particular
molecular subtypes of breast cancer.
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